OBI Pharma and Novartis Partner to Develop Next-Generation ADC Therapies in Taiwan
OBI Pharma signs collaboration and license agreement with Novartis for its Obrion® ADC platform, with deal terms undisclosed. Get the key details here.
Research Desk
OBI Pharma, Inc. (4174.TWO) (“OBI”) has announced a collaboration and licensing agreement with Novartis Pharma AG (“Novartis”) to develop next-generation antibody-drug conjugates (ADCs) incorporating novel payloads through OBI’s proprietary technology platforms.
Collaboration Targets Next-Generation ADCs
Under the agreement, Novartis will obtain exclusive worldwide rights to OBI’s relevant patents and know-how associated with its ADC platform technologies for selected, undisclosed Novartis payload classes.
As part of the collaboration, OBI will evaluate novel linker approaches for use with Novartis’s payloads. Novartis will also have the option to expand the agreement to cover additional novel payload classes.
The agreement highlights the potential of OBI’s proprietary ADC technology platform and supports the company’s strategy of expanding the global application of its technologies. These include GlycOBI, EndoSymeOBI, HYPrOBI, and GlycOBI DUO.
Leadership Comments on the Partnership
Ya-Chi Chen, Pharm.D., acting Chief Executive Officer of OBI Pharma, Inc., said, “We are delighted to enter into this agreement with Novartis, a leading pharmaceutical company in innovative oncology drug development with extensive commercialization capabilities. This agreement recognizes the scientific and commercial potential of OBI’s proprietary ADC technologies and reflects the value of our differentiated platform. By combining OBI’s ADC expertise with Novartis’s resources and capabilities, we aim to advance next-generation therapies that could deliver meaningful benefits to patients.”
Shiva Malek, Global Head of Oncology, Biomedical Research at Novartis, said, “Engaging with OBI’s expertise and technologies in antibody-drug conjugation to create potential ADCs with novel payloads is an important part of our oncology ADC strategy. This collaboration supports our ambition to innovate novel therapies and potentially expand treatment options for patients.”
Financial Terms of the Agreement
OBI will receive an upfront payment of USD 30 million under the agreement. The company is also eligible to receive development, regulatory, and commercial milestone payments, with the total potential deal value exceeding USD 2 billion.
Additionally, OBI will be eligible for tiered royalties on net sales of licensed products resulting from the collaboration.
Obrion ADC Technology Platform
OBI's proprietary Obrion ADC Technology Platform integrates multiple technologies to support the development of next-generation antibody-drug conjugates.
At its core is GlycOBI, a glycan-based conjugation technology featuring a flexible, plug-and-play design compatible with a broad range of antibodies, linkers, and payloads. It also supports different drug-to-antibody ratios (DARs).
The platform combines GlycOBI with EndoSymeOBI, OBI's proprietary dual-function enzymatic technology, and HYPrOBI, its highly hydrophilic and stable linker technology. Together, these technologies support the efficient and scalable production of site-specific, homogeneous ADCs under good manufacturing practice (GMP) conditions.
GlycOBI DUO further extends the platform's capabilities by supporting next-generation ADC formats, including dual-payload ADCs.
About OBI Pharma
Established in 2002 and headquartered in Taiwan, OBI Pharma is a clinical-stage global oncology company with operations in the United States and Australia.
The company focuses on developing innovative cancer therapeutics and advancing proprietary antibody-drug conjugate technologies to address unmet medical needs and provide new treatment options for patients.
Tracked in the database
Licensing and Collaboration Deals · Asia-Pacific
Licensing and Collaboration Deals
Asia-Pacific
Chemical
13 November 2026
2 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.